17.8704.79% ( -0.900 )
Delay Closed: Nov 18, 16:08:04News
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products | ZLAB Stock News
StockTitan·- Zai Lab announced the inclusion of five of its commercial medicines in China's 2026 National Reimbursement Drug List, featuring first-time listings for KarXT and VYVGART Hytrulo®. - The update successfully expands patient access to treatments for schizophrenia and generalized myasthenia gravis while maintaining coverage for three existing oncology and infectious disease products. - These newly listed and renewed therapies are scheduled to take effect on January 1, 2027, supporting the company's goal of broadening access to innovative medicines.Zai Lab Announces Participation in Investor Conferences in November 2026 | ZLAB Stock News
StockTitan·- Zai Lab Limited announced that its senior management team will participate in two major investor conferences in November 2026. - The company will attend the UBS Global Biopharma Conference on November 17, 2026, and the Jefferies Global Healthcare Conference on November 18 and 19, 2026. - Live webcasts and archived replays of the events will be accessible on the Investor Relations section of the company website.Zai Lab reports sustained biomarker inhibition with ZL-1503 in Phase 1 trial
PUBT·- Zai Lab reported positive preliminary results from a Phase 1/1b trial for its experimental atopic dermatitis treatment ZL-1503 in healthy volunteers. - The drug demonstrated sustained suppression of inflammatory biomarkers and an extended half-life supporting maintenance dosing every 12 weeks, with no serious adverse events reported. - Repeated-dose results in patients with moderate-to-severe atopic dermatitis are anticipated in the first half of 2027.Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing | ZLAB Stock News
StockTitan·- Zai Lab announced positive first-in-human Phase 1 results for its novel IL-13/IL-31Rα bispecific antibody, ZL-1503, in healthy volunteers. - The single-ascending-dose study demonstrated at least 90% inhibition of pSTAT6 through Week 12 at doses from 200 to 1,000 mg, along with an extended half-life of 40 to 50 days. - ZL-1503 was well tolerated with no serious adverse events, supporting upcoming multiple-ascending-dose trials in moderate-to-severe atopic dermatitis patients expected in the first half of 2027.Zai Lab drops 6%
Market Movers·Zai Lab Grants Options and Restricted Share Units to Employees
Tip Ranks·- Zai Lab Ltd issued share options and restricted share units to select employees. - The grants cover a total of 22,800 ADSs and 228,000 underlying shares. - Share options are set at an exercise price of US $26.86 per ADS and vest over 4 years.Zai Lab hits 52-week high
Market Movers·Is Zai Lab (ZLAB) A Bargain After New Trial Data And Fresh Funding?
Simplywall·- Zai Lab experienced a recent share price surge driven by positive Phase 1 cancer drug data, new equity funding, and its third quarter 2026 results. - Analyst consensus estimates a fair value of US$ 33.48 against a trading price of US$ 25.48, supported by plans for U.S. regulatory submissions and global expansion by 2028. - Potential risks include reliance on partnered assets, a slight decline in Q2 2026 China product revenue to US$ 105.8 million, and a price-to-sales ratio of 6.5 x compared to a fair ratio of 3.5 x.Early Trial Data Might Change The Case For Zai Lab Stock
Simplywall·- Zai Lab reported Q3 2026 revenue of US$108.21 million and a net loss of US$46.14 million alongside a recent equity financing of approximately US$250 million. - The fresh capital extends the funding runway for key pipeline drugs like zoci and ZL-1503 to support multiple registrational studies and a 2027 regulatory push. - Despite the extended runway, the company still faces execution risks, widening losses, and potential pricing pressures in China.Zai Lab (ZLAB) Advances Zoci Toward Phase 3 In Extrapulmonary Neuroendocrine Carcinomas
Simplywall·- Zai Lab released updated clinical data for zocilurtatug pelitecan in extrapulmonary neuroendocrine carcinomas, showing encouraging responses in a patient population with limited treatment options. - The biopharmaceutical company plans to pursue an accelerated approval pathway and launch a global Phase 3 trial for the drug in 2027. - This clinical progress extends the drug's potential reach into DLL3 expressing tumors and strengthens the company's oncology franchise strategy.Zai Lab Q3 2026 Earnings Call Transcript
benzinga_article·- Zai Lab reported third-quarter 2026 financial results with total revenue of $108.2 million and a strong cash position of $659.7 million, alongside a 2% sequential increase in net product revenue reflecting commercial business stabilization in China. - The company is advancing JOSI toward a potential US BLA submission in 2027 and a US launch in 2028, supported by recent $250 million financing and positive Phase 1 data demonstrating an 81.8% confirmed objective response rate in small cell lung cancer. - Key strategic initiatives include global Phase 3 studies for JOSI, ongoing T cell engager collaborations with Amgen and BI, and the continued development of the immunology pipeline featuring CL1503 for atopic dermatitis.
